ADMA Biologics ADMA Accrued Testing Current
Accrued Testing Current at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept adma:AccruedTestingCurrent.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's accrued testing current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's accrued testing current?
- ADMA Biologics (ADMA) reported accrued testing current of $389K in Q1 2026.
- How has ADMA Biologics's accrued testing current changed year-over-year?
- ADMA Biologics's accrued testing current decreased by 16.0% year-over-year, from $463K to $389K.
- What is the long-term trend for ADMA Biologics's accrued testing current?
- Over 4 years (2021 to 2025), ADMA Biologics's accrued testing current has grown at a -42.5% compound annual growth rate (CAGR), from $1.19M to $130K.
- What does accrued testing current mean?
- This represents current liabilities related to unpaid expenses for laboratory, quality control, or clinical testing services performed by third parties. It captures the short-term financial commitment for essential operational testing required in the manufacturing or development process.